European Medicines Agency: approval of new glucose-lowering medicines for type 2 diabetes

Bailey, Clifford J (2018). European Medicines Agency: approval of new glucose-lowering medicines for type 2 diabetes. Diabetes, Obesity and Metabolism, 20 (9), pp. 2057-2058.


Since 2005 all new glucose‐lowering medicines to be used in Europe have required approval by the European Medicines Agency (EMA) through a centralised procedure [1]. This involves assessment of a detailed file of data generated during the preclinical studies and phase 1‐3 clinical trials, along with the proposed product label. The file is subject to internal review and some aspects may also receive external review, giving rise to questions that are referred back to the sponsor and may lead to additional studies. The assessment is considered by the Committee for Medicinal Products for Human Use (CHMP) and if approval is recommended then a marketing authorisation is usually granted by the European Commission.

Publication DOI:
Divisions: Life & Health Sciences > Biosciences
Life & Health Sciences > Cell & Tissue Biomedical Research
Life & Health Sciences
Life & Health Sciences > Chronic and Communicable Conditions
Additional Information: This is the peer reviewed version of the following article: Bailey, C. J. (2018), European Medicines Agency: approval of new glucose‐lowering medicines for type 2 diabetes. Diabetes Obes Metab. Accepted Author Manuscript., which has been published in final form at  This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Full Text Link:
Related URLs: https://onlinel ... .1111/dom.13360 (Publisher URL)
Published Date: 2018-05-13
Published Online Date: 2018-05-13
Authors: Bailey, Clifford J ( 0000-0002-6998-6811)



Version: Accepted Version

| Preview

Export / Share Citation


Additional statistics for this record